AOD-9604 Peptide: HGH Fragment Lipolysis Research Overview

What is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191. With a molecular weight of 1815.1 Da, the fragment retains the lipolytic and lipogenesis-inhibition properties of the parent hGH molecule but, critically for research applications, does not engage the IGF-1 signalling axis. Researchers can access AOD-9604 research peptide from Advanced Peptide Science at 99%+ HPLC-verified purity.

Research Background and Development

AOD-9604 emerged from research investigating whether the diverse biological activities of human growth hormone could be dissected into separable functional domains. The C-terminal 16-residue fragment was identified as carrying the lipolytic activity of the parent hGH molecule while lacking the receptor-binding determinants required for IGF-1 axis activation. The resulting compound serves as a research-tool for investigating adipose tissue biology isolated from the confounding effects of full-length hGH.

Mechanism of Action

Mechanism research investigates AOD-9604 stimulation of adipocyte lipolysis and inhibition of lipogenesis pathways. Unlike intact human growth hormone, the fragment does not activate the IGF-1 receptor at downstream signalling magnitudes capable of driving systemic growth signalling — providing a research-clean intervention for adipose tissue investigation. Active research areas include beta-adrenergic receptor cross-talk in adipocytes, cAMP/PKA signalling driving hormone-sensitive lipase (HSL) phosphorylation, and downstream lipid droplet remodelling. The compound is also investigated in combination with metabolic research peptides via the Metabolic Blend (Semaglutide + AOD-9604) for combined incretin + lipolytic pathway research.

Key Research Findings

Lipolysis Stimulation

Research investigates AOD-9604 activation of adipocyte lipolytic cascades. The fragment is hypothesised to engage residual hGH-receptor binding sufficient to activate downstream cAMP/PKA signalling and HSL phosphorylation, but without engaging the full receptor dimerisation profile required for IGF-1 axis activation. This makes the compound a research tool for isolated lipolytic pathway investigation.

Lipogenesis Inhibition

Parallel research investigates AOD-9604 inhibition of lipogenesis pathways in adipocytes. Mechanistic studies focus on suppression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) activity in preclinical adipocyte models, alongside the lipolytic effects.

IGF-1 Axis Isolation

The defining research advantage of AOD-9604 is the absence of IGF-1 axis activation. Comparative research against intact hGH or against IGF-1 analogues such as IGF-1 LR3 enables dissection of lipolytic vs growth-signalling pathways that would otherwise be confounded in full-hGH research designs.

Research Applications and Comparison

AOD-9604 occupies a distinctive niche in the Metabolic & Weight Management research peptide category. Unlike GLP-1-class compounds (Semaglutide, Tirzepatide) which act primarily through incretin receptor pathways on pancreatic beta cells and CNS appetite circuits, AOD-9604 acts directly on adipocyte lipolytic signalling. The combined Metabolic Blend formulation co-administers AOD-9604 with Semaglutide for research investigating parallel incretin + direct lipolytic pathway effects within a single experimental model.

Research Specifications

Molecular Weight	1815.1 Da
Sequence	Synthetic fragment corresponding to amino acids 176-191 of human growth hormone
Receptor Activity	Adipocyte lipolytic signalling without IGF-1 axis activation
Format	Lyophilized powder in sterile vial
Purity	≥ 99% (HPLC verified)
Storage	-20 °C, protect from light

Frequently Asked Questions

What is the research significance of AOD-9604 fragment 176-191?

AOD-9604 corresponds to amino acids 176-191 of the C-terminal region of human growth hormone. The fragment retains the lipolytic activity of intact hGH but does not activate the IGF-1 axis — providing a research-clean intervention for adipose tissue biology research isolated from systemic growth signalling.

How does AOD-9604 differ from GLP-1 research peptides?

GLP-1 receptor agonists (Semaglutide, Tirzepatide) act through pancreatic insulin secretion and CNS appetite-circuit modulation. AOD-9604 acts directly on adipocyte lipolysis. The mechanisms are non-overlapping, enabling combined research via the Metabolic Blend.

Where can researchers source AOD-9604?

AOD-9604 research peptide is available at Advanced Peptide Science at 99%+ HPLC-verified purity with batch-specific COA available on request.

Is AOD-9604 approved for human use?

Advanced Peptide Science supplies AOD-9604 exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.

---

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.